Holding paper receipts for just 10 seconds can pose health risks, researchers warn
In an Apr. 14 statement, the Center for Environmental Health (CEH) announced a notice of violation for 32 retailers that allegedly had high levels of Bisphenol S (BPS) in their receipts.
In the official notice of violation on April 11, the companies named dozens of national corporations.
Men's Multivitamins Recalled Due To Undeclared Allergen: Fda
The organization described Bisphenol S (BPS) as the "lesser-known but harmful chemical cousin to BPA in receipt paper," and described the organic compound as "hormone-disrupting."
"BPS, like [Bisphenol A] … mimics estrogen and can disrupt the normal functioning of the body, including metabolism, growth and development, and reproduction," the statement said.
Read On The Fox News App
"Studies show that BPS can be absorbed through skin when handling receipt paper – even for short periods."
This Odd Dental Habit Could Spark Heart Health Risks, Experts Warn
The statement claimed that holding a BPS-laced receipt for just 10 seconds could have serious health consequences.
"Based on these studies and testing by an independent lab, the concentrations were so high that touching only one receipt with BPS for 10 seconds resulted in exposure above the safe harbor level, which requires a clear and reasonable warning to consumers," CEH Science Lead Mihir Vohra said in the press release.
CEH stated that a lawsuit will be filed against the alleged violators unless they agree to "provide clear and reasonable warnings" to consumers or "reformulate such products to eliminate the BPS exposures."
The retailers will also have to pay an "appropriate civil penalty."
The organization advised consumers to decline paper receipts whenever possible.
Click Here To Sign Up For Our Health Newsletter
"Store workers who must handle receipts should wear gloves if possible or avoid using alcohol-based hand cleaners before handling a receipt, because it can significantly increase the absorption of BPS," said CEH Senior Director Shakoora Azimi-Gaylon in the release.
"Receipts are made from thermal paper, which shouldn't be recycled because they contain bisphenols like BPA and BPS, which can contaminate the recycling stream and pose health and environmental risks."
Fox News senior medical analyst Dr. Marc Siegel noted that digital receipts are more prevalent than ever.
"We are definitely moving in the direction of digital receipts anyway," the medical expert told Fox News Digital.
Siegel also noted that many Americans are exposed to Bisphenol A (BPA) without noticing it – for example, it can commonly be found on smartphone cases, despite not being found on iPhones.
For more Health articles, visit www.foxnews.com/health.
More research needs to be done on the impact of "forever chemicals" like BPS, the doctor suggested.
"Forever chemicals are everywhere and there is a concern about fertility," Siegel cautioned.
"We need to do a better job of documenting and limiting exposure."
BPS has been scrutinized in recent years over its potential to adversely impact people's health.
In 2021, German researchers found that the chemical compound could "seriously damage" human brains after studying its effects on the nerve cells of goldfish.Original article source: Holding paper receipts for just 10 seconds can pose health risks, researchers warn
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 hours ago
- Medscape
FDA Declines to Approve New Melanoma Therapy
The FDA has declined to approve a new oncolytic immunotherapy, vusolimogene oderparepvec (RP1), to treat advanced melanoma. The agency recently issued a complete response letter to the company, Replimune Group, rejecting its biologics license application that sought approval for the new agent in combination with nivolumab (Opdivo) to treat adults with advanced melanoma. In the complete response letter, the FDA indicated that it can't approve the biologics license application for vusolimogene oderparepvec because the company's IGNYTE trial 'is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness,' Replimune explained in a press release. According to Replimune, the complete response letter also noted that the trial data 'cannot be adequately interpreted due to the heterogeneity of the patient population,' and that 'there are items related to the confirmatory trial study design which need to be addressed.' 'We are surprised by the FDA decision and disappointed for advanced melanoma patients who have limited treatment options, as highlighted by the granting of breakthrough status at the time we provided the IGNYTE primary data,' stated Sushil Patel, PhD, Replimune's chief executive officer. Vusolimogene oderparepvec is the lead product candidate for the biotech company. Patel further noted that the issues raised in the complete response letter were not 'raised by the agency in mid- and late-cycle reviews.' Additionally, he said, 'we had also aligned on the design of the confirmatory study.' The FDA's response to the biologics license application for the new agent, along with its recently announced policy requiring randomized, controlled trials for approval of COVID vaccines in healthy Americans younger than 65 years, may signal that the agency is taking a tougher stance on new drug approvals. Replimune plans to 'urgently interact with the FDA to find a path forward for the timely accelerated approval of RP1,' according to its statement. Sharon Worcester, MA, is an award-winning medical journalist based in Birmingham, Alabama, writing for Medscape Medical News, MDedge, and other affiliate sites. She currently covers oncology, but she has also written on a variety of other medical specialties and healthcare topics. She can be reached at sworcester@ or on X @SW_MedReporter.
Newsweek
9 hours ago
- Newsweek
Canned Fruit Recall Sparks Nationwide Warning to Customers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. W.W. Industrial Group is recalling Parashore brand pear slices in juice due to fears the product may contain elevated levels of lead and cadmium. Newsweek reached out to the company via phone Wednesday for comment and left a voicemail. Why It Matters Elevated levels of lead and cadmium can cause significant health problems, particularly among infants and children. The recall adds to a growing list of high-profile food safety actions, emphasizing the ongoing importance of vigilant federal oversight and thorough product testing to protect public health. Lead and cadmium are both toxic metals that can enter the food supply from environmental sources, such as contaminated soil or industrial byproducts. According to the U.S. Food and Drug Administration (FDA), lead exposure poses particular risks to young children, whose developing brains are highly susceptible to neurotoxic effects. Elevated lead intake in early childhood has been linked to long-term issues affecting learning and behavior. Cadmium contamination can arise from soil composition, industrial activities and certain manufacturing processes. Prolonged exposure to cadmium, especially at levels above the FDA's interim reference level, can affect kidney function and increase the risk of bone demineralization. While it is not possible to completely prevent cadmium from entering the food supply, manufacturers are legally required to minimize and monitor such risks. Numerous recalls have been initiated in 2025 due to the potential for damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the FDA, the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. What To Know In the FDA alert, the recalled sliced pears were distributed throughout grocery outlet stores in California and other locations across the United States. The products were sold in a 15-ounce can with a UPC number of #704817164237. "The specific lot found positive for heavy metals was Lot 3700/01172 6122J, Prod: 02/19/2024, Best by 2/19/2027," the FDA warns. The agency adds that there had been no reported illnesses related to the recall as of Tuesday. What People Are Saying The FDA alert, in part: "The heavy metal contamination was discovered via sampling by the Maryland Department of Health which is part of the FDA Laboratory Flexible Funding Model program. The company has recalled the products and is continuing an investigation to determine cause." What Happens Next Customers who have purchased the recalled pear slices are urged to throw them away or return the product to the original place of purchase for a full refund, the FDA says. People with additional questions can contact W.W. Industrial Group via phone at 516- 676-9188 from 10 a.m. to 4 p.m. ET weekdays.
Bloomberg
11 hours ago
- Bloomberg
Sarepta Needs to Show FDA Elevidys Won't Cause More Deaths
The Food and Drug Administration won't sign off on Sarepta Therapeutics Inc. bringing its controversial gene therapy back to the market until the company can persuade US regulators that it won't cause more deaths, according to an official familiar with the situation. The FDA has not seen a convincing explanation as to why Sarepta's gene therapy for Duchenne muscular dystrophy, Elevidys, was tied to two fatal cases of liver failure, the official said, and there may be no single, easily addressable problem the company can quickly fix. A third fatal case of liver failure that occurred during a trial of a separate but similar Sarepta gene therapy is unquestionably relevant information to the safety of Elevidys, said the official, who declined to be identified because the agency's deliberations are private.
